<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05057312</url>
  </required_header>
  <id_info>
    <org_study_id>2020-1142</org_study_id>
    <nct_id>NCT05057312</nct_id>
  </id_info>
  <brief_title>Promoting HPV Vaccination Among Young Adults in Texas</brief_title>
  <official_title>Promoting HPV Vaccination Among Young Adults in Texas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study uses a randomized controlled trial (RCT) to test an innovative multilevel&#xD;
      intervention to increase HPV vaccination rates among young adults. The two primary outcomes&#xD;
      will be the rate of HPV vaccination initiation by 3-month follow-up and rate of HPV&#xD;
      vaccination completion by 9-month follow-up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective&#xD;
&#xD;
      To use a randomized controlled trial (RCT) to test an innovative multilevel intervention to&#xD;
      increase HPV vaccination rates among young adults.&#xD;
&#xD;
      Secondary Objective(s)&#xD;
&#xD;
      To gain insight into mechanisms of the intervention's efficacy, individual differences, and&#xD;
      implementation of the intervention using mixed methods.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 26, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Partially masked for Care Provider to certain groups.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The two primary outcomes will be the rate of HPV vaccination initiation by 3-month follow-up and rate of HPV vaccination completion by 9-month follow-up</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>HPV</condition>
  <condition>Related Malignancy</condition>
  <condition>Related Carcinoma</condition>
  <arm_group>
    <arm_group_label>Experimental arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Video narrative persuasion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Written narrative Persuasion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enhanced Access to HPV vaccines</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Video narrative persuasion; Enhanced Access to HPV vaccines</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental arm 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Written narrative Persuasion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control/ active comparator Arm 6</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>CDC information</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Experimental arm 1</intervention_name>
    <description>Video narrative persuasion</description>
    <arm_group_label>Experimental arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Experimental arm 2</intervention_name>
    <description>Written narrative Persuasion</description>
    <arm_group_label>Experimental arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Experimental arm 3</intervention_name>
    <description>Enhanced Access to HPV vaccines</description>
    <arm_group_label>Experimental arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Experimental arm 4</intervention_name>
    <description>Video narrative persuasion; Enhanced Access to HPV vaccines</description>
    <arm_group_label>Experimental arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Experimental arm 5</intervention_name>
    <description>Written narrative Persuasion; Enhanced access to HPV vaccines</description>
    <arm_group_label>Experimental arm 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-26 years. This criterion is based on the CDC recommendation of vaccination up&#xD;
             to 26 years of age5 and the fact that individuals 18 years and older can consent by&#xD;
             themselves for on-site vaccination.&#xD;
&#xD;
          -  Ability to read and understand English.&#xD;
&#xD;
          -  Self-identification as not yet having received any HPV vaccine injections.&#xD;
             Self-identification is justified because it is safe to be vaccinated again, which&#xD;
             could happen if a previously vaccinated person forgets their vaccination. Furthermore,&#xD;
             in a person previously vaccinated with an older version of the vaccine, which targeted&#xD;
             fewer HPV types, receiving the newer version would be advantageous and not cause any&#xD;
             harm. Alternatives to self-identification, such as obtaining medical records from&#xD;
             doctors' offices, would be very challenging for young adults, especially for those who&#xD;
             do not remember when and where they might have received vaccination.&#xD;
&#xD;
          -  Access to a smart phone, tablet or computer that is connected to the internet&#xD;
&#xD;
          -  Current enrollment in one of the participating schools with an anticipated continuous&#xD;
             enrollment of at least 9 months.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Being pregnant&#xD;
&#xD;
          -  Having a life-threatening allergy to any component of the HPV vaccine. Additional&#xD;
             screening for pregnancy and allergy will be performed by the clinics and pharmacy when&#xD;
             students present for vaccination as part of routine care. We will also query&#xD;
             participants' pregnancy status at baseline and the 3-month follow-up. Participants who&#xD;
             report a pregnancy will be dropped from the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qian Lu</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qian Lu</last_name>
    <phone>(713) 745-8324</phone>
    <email>qlu@mdanderson.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lenna Dawkins-Moultin</last_name>
    <phone>713-792-0005</phone>
    <email>ldawkins@mdanderson.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qian Lu</last_name>
      <phone>713-745-8324</phone>
      <email>qlu@mdanderson.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>M D Anderson Cancer Center</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 25, 2021</study_first_submitted>
  <study_first_submitted_qc>September 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

